• Medicine
• Published in
  The New England journal of…
  2005
• DOI:10.1056/NEJMoa050493

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

@article{Bresalier2005CardiovascularEA,
  title={Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.},
  author={Robert S. Bresalier and Robert S. Sandler and Hui Quan and James A. Bolognese and Bettina Oxenius and Kevin Horgan and Christopher Lines and Robert Riddell and Dion G. Morton and Angel Lanas and Marvin A. Konstam and John A Baron},
  journal={The New England journal of medicine},
  year={2005},
  volume={352 11},
  pages={
          1092-102
        }
}

• Robert S. Bresalier, Robert S. Sandler, +9 authors John A Baron

BACKGROUND Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report on the cardiovascular outcomes associated with the use of the selective COX-2 inhibitor rofecoxib in a long-term, multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of three years of treatment with rofecoxib on the risk of recurrent neoplastic polyps of… CONTINUE READING

View PDF

Save to Library

Create Alert

Cite